HYDROFARM HOLDINGS GROUP, INC. 8-K

What Happened
Hydrofarm Holdings Group, Inc. (HYFM) filed an 8‑K reporting that Nasdaq notified the company it is not in compliance with the $2.5 million minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). After Nasdaq granted an extension based on Hydrofarm’s plan, a July 2, 2026 Nasdaq determination found the company did not meet the terms of that extension. Hydrofarm timely requested a hearing before the Nasdaq Hearing Panel on July 9, 2026, which stayed further Nasdaq action pending the hearing. Separately, on July 6, 2026 Nasdaq notified the company it is not in compliance with the minimum $1.00 bid‑price requirement under Listing Rule 5550(a)(2); a 180‑day cure period applies for the bid‑price deficiency.

Key Details

• Nasdaq equity rule at issue: Listing Rule 5550(b)(1) — $2.5 million minimum stockholders’ equity.
• Timeline: initial Nasdaq notice April 1, 2026; company submissions May 18 and June 8, 2026; extension granted June 16, 2026; Nasdaq determination of non‑compliance July 2, 2026; hearing requested July 9, 2026.
• Bid price notice: July 6, 2026 — failure to maintain $1.00 minimum closing bid for prior 30 consecutive business days; 180 calendar‑day cure period available; compliance can be confirmed if the stock closes ≥ $1.00 for 10 consecutive business days.
• Company is considering all options to regain compliance but expressly states there is no assurance it will succeed; forward‑looking statements and related risks were included.

Why It Matters
This filing signals that Hydrofarm faces potential delisting risks on Nasdaq if it cannot restore its stockholders’ equity or bid price to meet Nasdaq standards. For investors, delisting could reduce liquidity and limit access to broader capital markets; the company’s request for a hearing temporarily halts Nasdaq’s next steps while the process plays out. Monitor HYFM for hearing outcomes, any Nasdaq extensions, or announced measures (e.g., capital raises, reverse stock splits, or other remedies) intended to regain compliance.